understanding parkinson`s disease

UNDERSTANDING PARKINSON’S DISEASE:
CELL VULNERABILITY AND DISEASE PROGRESSION
Universidad de Navarra
Jueves, 11 de abril
Salón de Actos
CIMA
1 al día
rasagilina
Prolongando el presente
Contacto Secretaría Técnica:
Cristina Canciani
Tel.: 948 194 700 ext. 2013
[email protected]
INSCRIPCIÓN OBLIGATORIA Y GRATUITA
1 al día
rasagilina
Prolongando el presente
Viernes, 12 de abril
Salón de Actos
Edificio de Biblioteca de Ciencias
Facultad de Medicina
Universidad de Navarra
Jueves, 11
30 AÑOS DE ENFERMEDAD DE PARKINSON Y TRASTORNOS DEL MOVIMIENTO EN PAMPLONA
17.30 Bienvenida Dres. N. García, E. Martínez Vila, JA Obeso
17. 45
Mesa Redonda Avances neurocientíficos en la enfermedad de Parkinson. ¿Qué ha cambiado?
M. Alegre (Pamplona)
F. Alonso (Madrid)
J. Blesa (Nueva York)
T. Herrero (Castellón)
18.15 Mesa Redonda Avances en el tratamiento en la enfermedad de Parkinson. ¿Qué ha cambiado?
F. Grandas, (Madrid)
J. Guridi (Pamplona)
R. Luquín (Pamplona)
MC Rodríguez-Oroz (San Sebastián)
J. Vaamonde (Ciudad Real)
18.45
Debate General
19.00 - 19.30
Conferencia de Clausura. Animal models of Parkinson’s disease. Facts and Fancy.
Prof. E. Bezard (Bordeaux)
11.50 - 12.10
Neurodegeneration of the nigro-striatal projection: Where does it begin?
R. Burke (New York)
12.10 -12.30 Neurodegeneration/neuroprotection of the nigro-striatal projection: Role of striatal interneurons
J. Lopez Barneo (Seville)
General Discussion
12.30
13.00
UNDERSTANDING PARKINSON’S DISEASE: CELL VULNERABILITY AND DISEASE PROGRESSION
8.55 Welcome JA Obeso and M. Rodriguez, Chair
Introduction
9.00 - 9.20 The Clinical Scenario: From patients to experiments and back to Parkinson’s disease
JA Obeso (Pamplona)
Break
Dopamine, the Basal Ganglia and Parkinson’s disease
The need to cope with automatic and goal directed behavior.
P. Redgrave (Sheffield)
13.30
Understanding Parkinson’s disease: A holistic view.
M. Rodriguez (Tenerife)
General Discussion
14.00
Viernes, 12
Lunch Break
The Pathology of
Parkinson’s disease
E. Bezard (Bordeaux) and J.L. Lanciego (Pamplona), Chair
15. 00
Michael J. Fox Foundation Research Priorities: What we think is important
B. Fiske (New York)
15.20
Synuclein deposition vs. cell loss in PD: Which explains what?
G. Halliday (Sydney)
Disease Progression
9.20 - 9.40 Onset and evolution of nigro-striatal degeneration in Parkinson’s disease
J. Kordower (Chicago)
15.50
How does it happen and what can be done?
P. Brundin (Grand Rapid, Michigan)
9.40 - 10.00 In vivo assessment of nigro-striatal activity throughout evolution.
J. Stoessel (Vancouver)
General Discussion
16. 30
10.30 Break
The experimental scenario
11.00 - 11.30
From animal models to patients and back to the laboratory
J. Surmeier (Chicago)
Mechanisms of Cell Vulnerability
11.30 - 11.50
The dopaminergic system and axonal branching.
P. Bolam (Oxford)
General Discussion
Break
Therapeutic Challenges and Opportunities
17.00
The rasaligine trial for cognitive impairment in PD.
D. Weintraub (Philadelphia)
17.30 Closing Lecture: Can we develop a neuroprotective therapy for PD?
C W Olanow. (New York)
18.00
Closing remarks
JA Obeso (Pamplona) y M. Rodriguez (Tenerife)